Semaglutide May Be Useful in Reducing Dry Macular Degeneration and Glaucoma

 A recent study published in Ophthalmology demonstrated GLP-1 receptor agonists were associated with reduced hazard of nonexudative AMD. Notably, GLP-1 receptor agonists also significantly reduced the risk of exudative AMD and POAG compared to insulin after three years.

“The consistency of these findings across multiple comparisons suggests a potential benefit of GLP-1RAs in mitigating the risk of nonexudative AMD,” the researchers wrote in their paper. “Demonstrating a reduction in risk of POAG without a significant impact on the rate of ocular hypertension could indicate the protective effect is separate from lowering intraocular pressure.”